445
Views
5
CrossRef citations to date
0
Altmetric
Review

The up-to-date role of biologics for the treatment of chronic lymphocytic leukemia

, & ORCID Icon
Pages 799-812 | Received 28 Nov 2019, Accepted 21 Feb 2020, Published online: 03 Mar 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Pawel Robak & Tadeusz Robak. (2023) Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. Expert Opinion on Biological Therapy 23:1, pages 21-35.
Read now

Articles from other publishers (4)

Qikai Zhang, Zongsi Zhu, Jiaqiang Guan, Yingying Hu, Wenjin Zhou, Wanchun Ye, Bijing Lin, Shanshan Weng, Yuemiao Chen & Cuiping Zheng. (2022) Hes1 Controls Proliferation and Apoptosis in Chronic Lymphoblastic Leukemia Cells by Modulating PTEN Expression. Molecular Biotechnology 64:12, pages 1419-1430.
Crossref
Lauren J. Fried, Maressa C. Criscito, Mary L. Stevenson & Miriam K. Pomeranz. (2021) Chronic lymphocytic leukemia and the skin: implications for the dermatologist. International Journal of Dermatology 61:5, pages 519-531.
Crossref
Jean-François Lesesve & Pierre Feugier. (2021) Leucémie lymphoïde chronique : de la biologie à la thérapeutique. Revue Francophone des Laboratoires 2021:532, pages 32-43.
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.